{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:33:47Z","timestamp":1790181227742,"version":"4.1.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jdcr.2025.06.027","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T08:20:27Z","timestamp":1751358027000},"page":"105-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Dupilumab for management of capecitabine-induced hand-foot syndrome"],"prefix":"10.1016","volume":"63","author":[{"given":"Ian","family":"Nykaza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Sanford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1297-123X","authenticated-orcid":false,"given":"Allison","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jdcr.2025.06.027_bib1","doi-asserted-by":"crossref","first-page":"442","DOI":"10.4081\/oncol.2020.442","article-title":"Management of cytotoxic chemotherapy-induced hand-foot syndrome","volume":"14","author":"Kwakman","year":"2020","journal-title":"Oncol Rev"},{"issue":"6","key":"10.1016\/j.jdcr.2025.06.027_bib2","first-page":"345","article-title":"Hand-foot syndrome in cancer patients on capecitabine: examining prevalence, impacts, and associated risk factors at a cancer centre in Malaysia","volume":"32","author":"King","year":"2024","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.jdcr.2025.06.027_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s40268-016-0154-8","article-title":"Tolerability of capecitabine monotherapy in metastatic colorectal cancer: a real-world study","volume":"17","author":"Leicher","year":"2017","journal-title":"Drugs R D"},{"issue":"3","key":"10.1016\/j.jdcr.2025.06.027_bib4","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10549-012-2288-x","article-title":"Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer","volume":"136","author":"Blum","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"10.1016\/j.jdcr.2025.06.027_bib5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41416-022-02039-3","article-title":"Capecitabine induces hand-foot syndrome through elevated thymidine phosphorylase-mediated locoregional toxicity and GSDME-driven pyroptosis that can be relieved by tipiracil","volume":"128","author":"Yang","year":"2023","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.jdcr.2025.06.027_bib6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1365-2125.2008.03159.x","article-title":"Candidate mechanisms for capecitabine-related hand-foot syndrome","volume":"66","author":"Milano","year":"2008","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.jdcr.2025.06.027_bib7","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1021\/acs.chemrestox.6b00215","article-title":"Possible pathways of capecitabine-induced hand-foot syndrome","volume":"29","author":"Lou","year":"2016","journal-title":"Chem Res Toxicol"},{"issue":"6","key":"10.1016\/j.jdcr.2025.06.027_bib8","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1007\/s00432-010-0958-9","article-title":"The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II\/III colorectal cancer: a phase II randomized prospective study","volume":"137","author":"Zhang","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"10.1016\/j.jdcr.2025.06.027_bib9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jaci.2022.09.012","article-title":"Mechanisms by which dupilumab normalizes eicosanoid metabolism and restores aspirin-tolerance in AERD: a hypothesis","volume":"151","author":"Picado","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"15","key":"10.1016\/j.jdcr.2025.06.027_bib10","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1200\/JCO.23.01730","article-title":"Topical diclofenac for prevention of capecitabine-associated hand-foot syndrome: a double-blind randomized controlled trial","volume":"42","author":"Santhosh","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512625002838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512625002838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T23:55:37Z","timestamp":1758671737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512625002838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":10,"alternative-id":["S2352512625002838"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2025.06.027","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dupilumab for management of capecitabine-induced hand-foot syndrome","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2025.06.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}